Skip to content

SIT LESS 4: How Does Reducing Sitting Time Improve Glucose and Lipid Metabolism?

SIT LESS 4: How Does Reducing Sitting Time Improve Glucose and Lipid Metabolism? A Study to Identify Underlying Mechanisms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03912922
Acronym
SITLESS4
Enrollment
12
Registered
2019-04-11
Start date
2017-12-15
Completion date
2020-03-13
Last updated
2021-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Keywords

insulin sensitivity, sitting time

Brief summary

Research has shown that replacing sitting time with low intensity physical activity (such as slowly walking and standing) has beneficial effects on metabolic health, like insulin sensitivity, comparable to improvements after sitting all day in combination with 1h streneous exercise. The main objective of this study is to investigate the underlying mechanisms responsible for improved insulin sensitivity after 4 days of sitting less compared to sitting and exercise in healthy obese women. Our secondary objective is to investigate the effects of sitting less on cardio metabolic parameters.

Interventions

OTHERActivity regime

Activity regime of 4 days followed by a test day.

Sponsors

Dutch Heart Foundation
CollaboratorOTHER
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Signed informed consent * Caucasian * Postmenopausal women * Aged 45-70 years at start of the study * Body mass index (BMI) 25 - 35 kg/m2 * Stable dietary habits (no weight loss or gain \>5kg in the past 3 months) * Sedentary lifestyle (not more than 2,5 hours of exercise per week in the past 3 months)

Exclusion criteria

* Not able to complete the sitless try-out day according to the protocol * Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other) * No use of medication interfering with investigated study parameters (as determined by responsible physician) * Alcohol consumption of \>2 servings per day * Smoking in the past 6 months * Participation in another biomedical trial which may have an effect on insulin sensitivity less than one month before the start of the study (screening visit) * Mental or physical disability which interferes with physical activity * Subjects with contra-indications for magnetic resonance imaging (MRI) * Reported participation in night shift work 2 weeks prior to the start of the study (screening visit) and during study participation. Night work is defined as working between midnight and 6.00 AM.

Design outcomes

Primary

MeasureTime frameDescription
Insulin sensitivityDay 5 of intervention period2-step hyperinsulinemic euglycemic clamp

Secondary

MeasureTime frameDescription
ex vivo skeletal muscle mitochondrial respirationDay 5 of intervention periodoxygraph
substrate oxidationDay 5 of intervention periodindirect calorimetry RER
Intrahepatic lipid contentDay 5 of intervention periodmagnetic resonance spectroscopy
Blood pressureDay 5 of intervention periodaverage resting blood pressure over 30 minutes
Plasma cardio metabolic markersDay 5 of intervention periodendothelial dysfunction score (average Z-score of log transformed plasma sVCAM1, sICAM1 and sE-selectin)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026